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OBJECTIVE—Rodent insulinoma cell lines may serve as a model
for designing continuously replicating human -cell lines and pro-
vide clues as to the central cell cycle regulatory molecules in the
-cell.
RESEARCH DESIGN AND METHODS—We performed a com-
prehensive G1/S proteome analysis on the four most widely
studied rodent insulinoma cell lines and deﬁned their ﬂow
cytometric proﬁles and growth characteristics.
RESULTS—1) Despite their common T-antigen–derived origins,
MIN6 and BTC3 cells display markedly different G1/S expression
proﬁles; 2) despite their common radiation origins, RINm5F and
INS1 cells display striking differences in cell cycle protein
proﬁles; 3) phosphorylation of pRb is absent in INS1 and RINm5F
cells; 4) cyclin D2 is absent in RINm5F and BTC3 cells and
therefore apparently dispensable for their proliferation; 5) every
cell cycle inhibitor is upregulated, presumably in a futile attempt
to halt proliferation; 6) among the G1/S proteome members,
seven are pro-proliferation molecules: cyclin-dependent kinase-1,
-2, -4, and -6 and cyclins A, E, and D3; and 7) overexpression of
the combination of these seven converts arrested proliferation
rates in primary rat -cells to those in insulinoma cells. Unfor-
tunately, this therapeutic overexpression appears to mildly at-
tenuate -cell differentiation and function.
CONCLUSIONS—These studies underscore the importance of
characterizing the cell cycle at the protein level in rodent
insulinoma cell lines. They also emphasize the hazards of inter-
preting data from rodent insulinoma cell lines as modeling
normal cell cycle progression. Most importantly, they provide
seven candidate targets for inducing proliferation in human
-cells. Diabetes 57:3056–3068, 2008
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utrients, growth factors, and physiological
states such as obesity and pregnancy can in-
duce -cell replication. However, the molecular
pathways that regulate DNA synthesis and mi-
tosis in -cells have only recently begun to be elucidated.
Most insight into pancreatic -cell cycle control is derived
from studies in mice with targeted mutations in either the
inhibitors or activators of cell cycle progression. For
example, inactivating mutations in several cell cycle con-
trol molecules have revealed roles for p27, p18, p16,
menin, pRb, p53, cyclin D1, cyclin D2, cdk4, E2F1, and
E2F2 (1,2). These studies suggest that the G1/S checkpoint
is especially important for the control of the cell cycle in
pancreatic -cells.
Other attractive models in which to study -cell cycle
replication are rodent insulinoma cell lines, which are
widely used as models for -cell signaling, function, and
replication (3). The four cell lines most widely used in
-cell research are MIN6, BTC3, INS1, and RINm5F cells.
MIN6 and BTC3 cells are related lines that were generated
by transgenic overexpression of the large T-antigen of the
SV40 virus in mouse -cells (3,4,5). INS1 and RINm5F are
also related cell lines that were derived from radiation-
induced tumors in rats (3,6,7). These cell lines vary in
characteristics, but all are at least partially differentiated
and proliferate more rapidly than normal -cells. Surpris-
ingly, despite their extensive use in the ﬁeld of -cell
biology, there is almost no information regarding the
mechanisms that lead to their loss of normal cell cycle
control (3–7).
The lack of a continuously growing human -cell line
suggests the possibility that lessons learned from rodent
insulinoma lines may offer clues on how to generate
corresponding human -cell lines that may be useful for
research and for cell replacement therapy of diabetes. We
therefore examined the G1/S proteome of these four
rodent insulinoma cell lines and compared them with
primary islets in hope that these cell lines might reveal
common mechanisms that lead to continuous proliferation
of insulin-secreting cells and potential targets to induce
proliferation in normal -cells.
As has been described previously in most human
cancers (8–10), comprehensive analysis revealed multi-
ple abnormalities in G1/S control in each of the four cell
lines. Interestingly, despite their common origins (X-
radiation in the rat cell lines or T-antigen overexpres-
sion in the mouse lines), insulinomas of common origin
display very different G1/S proﬁles. In addition, several
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arrest or allowing cell cycle progression in normal
rodent islets, e.g., cyclin D2, are entirely dispensable in
mouse and rat insulinoma lines. Finally, seven G1/S
molecules that are capable of stimulating -cell cycle
progression were identiﬁed. These observations have
important cautionary implications for the use of the four
cell lines as models of “normal” -cell replication. They
also suggest strategies for developing continuously
growing human -cell lines.
RESEARCH DESIGN AND METHODS
Cell lines. BTC3, MIN6, INS1, and RINm5F cells were obtained from Dr.
Lydia Aguilar-Bryan (PNRI, Seattle, WA), Susumu Seino (Kobe University,
Kobe, Japan), Dr. Doris Stoffer (University of Pennsylvania, Philadelphia, PA),
and American Type Culture Collection, respectively. They were uniformly
studied at 80% conﬂuence. Each cell line was cultured in its standard tissue
culture medium: BTC3 and MIN6 in Dulbecco’s modiﬁed Eagle’s medium (20
mmol/l glucose with 10% FCS); and INS1 and RINm5F in RPMI (11 and 5.5
mmol/l glucose, respectively, and 10% FCS; Invitrogen, Carlsbad, CA). MIN6
cells require 50 mol/l -mercaptoethanol, and INS1 cells require 10 mmol/l
HEPES, 2 mmol/l glutamine, 1 mmol/l sodium pyruvate, and 50 mol/l
-mercaptoethanol.
Cell cycle distribution and cell growth. Trypsinized cells from cell lines
and isolated islets were ﬁxed with 70% ethanol and analyzed using ﬂow
cytometry (ﬂuorescence-activated cell sorting [FACS]). On the day of FACS,
ﬁxed cells were pelleted and resuspended in a PBS solution containing 50
g/ml propidium iodide (Sigma, St. Louis, MO), 100 units/ml RNase A (Sigma),
and 1 g/l glucose. Stained cells were ﬁltered through a 30-m nylon mesh, and
DNA content was analyzed on a ﬂow cytometer (Becton Dickinson, Franklin
Rat Islets INS1 
MIN6 
RINm5  F 
BTC3 
G  0 /G  1 : 95.8 ± 0.  9 
S: 1.3 ± 0.  2 
G  2 /M: 2.8 ± 1.  0 
G  0 /G  1 : 76.9 ± 0.  4 
S: 16.3 ± 0.  3 
G  2 /M: 6.4 ± 0.  4 
G  0 /G  1 : 53.4 ± 4.  8 
S: 19.8 ± 3.  1 
G  2 /M: 25.9 ± 5.  9 
G  0 /G  1 : 96.5 ± 1.  1 
S: 1.0 ± 0.  4 
G  2 /M: 2.6 ± 0.  8 
G  0 /G  1 : 79.5 ± 4.  5 
S: 13.4 ± 2.  1 
G  2 /M: 7.3 ± 3.  0 
G  0 /G  1 : 76.3 ± 2.  1 
S: 15.8 ± 2.  3 
G  2 /M: 8.1 ± 1.  6 
C
e
l
l
 
N
u
m
b
e
r
 
(
%
 
)
 
C
e
l
l
 
N
u
m
b
e
r
 
(
%
 
)
 
Mouse Islets 
S 
G2/M 
S 
G2/M 
S 
G2/M 
S 
G2/M 
S 
G2/M 
S 
G2/M 
G0/G  1 
G0/G  1  G0/G  1 
G0/G  1 
G0/G  1  G0/G  1 
A 
C
e
l
l
 
N
u
m
b
e
r
 
/
 
 
W
e
 
l
l
 
0 
50,000 
100,00  0 
150,00  0 
200,00  0 
250,00  0 
300,00  0 
12  3456 
MIN6      n =   9 
BTC3     n =   9 
INS1       n =   9 
RINm5F  n =   9 
Days in Cultur  e 
p < 0.05 
vs. Murine Line  s 
p < 0.05 
vs. MIN-  6 
B 
DNA content  DNA content  DNA content 
FIG. 1. Proliferation rates for the four rodent insulinoma cell lines. A:
Flow cytometric analysis of cell cycle distribution. Results (mean 
SE) display the percentage of cells in each phase of the cell cycle. Each
ﬁgure is representative of ﬁve experiments. B: Growth curves for the
four cell lines. Bars indicate SE. On day 0, 10,000 cells were plated.
Each line represents three separate experiments performed in tripli-
cate (n  9).
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DIABETES, VOL. 57, NOVEMBER 2008 3057Lakes, NJ). To examine growth, 10,000 cells were plated per well in 24-well
tissue culture plates. Cells were counted using a hemocytometer in triplicate
every day for 6 days after initial plating.
Adenoviral production. Adenoviruses (Ad.5 or pAd-Easy system) were
prepared according to methods that we have previously described in detail
(11–14). Multiplicity of infection (MOI) was determined by optical density at
260 nm and by plaque assay.
Islet isolation, adenoviral transduction, and glucose-stimulated insulin
secretion. All animal studies were performed in compliance with and with
approval of the University of Pittsburgh Institutional Care and Use Committee.
Islets were isolated from 8- to 10-week-old Sprague-Dawley rats (Taconic,
Germantown, NY) and 8- to 12-week-old CD1 and C57Bl6 mice (The Jackson
Laboratories, Bar Harbor, ME) as previously described (14,15). Isolated rat
islets were cultured in RPMI medium supplemented with 10% FCS, 5.5 mmol/l
FIG. 2. The G1/S proteome of the four rodent insulinoma cell lines. MIN6 and BTC3 cell lines are compared with mouse islets (M isl). INS1 (INS)
and RIN (RINm5F) lines are compared with rat islets (R isl). Actin blots are representative and demonstrate even loading. A: Western-blot
analysis of T-Ag, pocket proteins, and the E2F transcription factor family. The bottom left panel shows induction of pRb phosphorylation in INS1
cells that have been transduced with the combination of the adenoviruses Ad.cdk4 plus Ad.cyclin D1. B: The cyclin D1, D2, and D3 and cdk-4 and
-6 family. C: The cdk-1/cdc2 and cdk-2 and cyclin A and E family. D: The INK4 family, the CIP/KIP family, and the tumor suppressor, menin. E: The
tumor suppressor, p53, its regulatory protein MDM2, and the Id family. Each blot represents three to ﬁve immunoblots.
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3058 DIABETES, VOL. 57, NOVEMBER 2008glucose, and penicillin-streptomycin for 24 h before adenoviral transduction.
Islets were transduced in serum-free medium for1ha t37°C with adenovi-
ruses containing the cDNAs for green ﬂuorescent protein (GFP); human cdk-1,
-2, -4, and -6; or cyclin A, D1, and E individually or in combination (“Combo”)
as detailed in RESULTS and in the ﬁgure legends. Islets were then incubated for
72 h in RPMI supplemented with 10% FCS and 5.5 mmol/l glucose, unless
otherwise stated. For glucose-stimulated insulin secretion (GSIS), static
assays were performed as described previously (11,14,16,17) using the ALPCO
(Salem, NH) ultrasensitive insulin enzyme immunosorbent assay. Matched
islet equivalents (IE) were hand-picked on the day of GSIS, 48 h after
adenoviral transduction.
Western blot analysis. Protein extracts and immunoblotting of the four cell
lines as well from mouse and rat islets (24 h after isolation) were performed
as reported previously (16,17) using previously published primary and sec-
ondary antibodies. Fresh membranes were used for immunoblots for all G1/S
members.
Quantiﬁcation of -cell proliferation and cell death. BrdU (10 g/ml;
Sigma) was added to the culture media 24 h before ﬁxation. Islets were ﬁxed
in Bouin’s solution for 1 h, washed with water, and then stored in 10% neutral
buffered formalin until embedding. To quantitate -cell proliferation, 5-m
sections were double-stained with anti-insulin (Dako, Carpinteria, CA) and
anti–Ki-67 (Lab Vision, Fremont, CA) or anti-BrdU (Abcam, Cambridge, MA).
To determine -cell death, islet sections were stained for apoptotic cells using
terminal deoxynucleotidyl-mediated dUTP nick-end labeling (TUNEL)
(Roche, Indianapolis, IN) and anti-insulin.
Real-time PCR. Quantitative PCR was performed using standard methods
and an ABI 7300 Real-Time PCR System. The relative quantiﬁcation for a given
gene was corrected to the -actin mRNA values. The sequences of the primers
are included in supplemental Table 1, which is available in an online appendix
at http://dx.doi.org/10.2337/db08-0393.
Islet transplant studies. Rat islets were transduced 24 h after the isolation;
24 h after transduction, the islets were transplanted into NOD-SCID mice
using procedures previously described (11). One rat IE was deﬁned as being
125 m in diameter.
Statistics. For all studies, Student’s two-tailed unpaired t test was performed
using Microsoft Excel. P values 0.05 were considered to be signiﬁcant. Bars
in the ﬁgures indicate SE.
RESULTS
Growth characteristics of BTC3, MIN6, INS1, and
RINm5F cells. To conﬁrm that the four insulinoma cell
lines replicate more rapidly than normal rodent -cells, the
three cell cycle phases (G0/G1, S, and G2/M) were exam-
FIG. 2. Continued
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MIN6) were compared with isolated primary mouse islets,
whereas the two rat lines (RINm5F and INS1) were com-
pared with isolated primary rat islet cells. Unlike primary
islet cells, which are arrested in G0/G1 (96%) (1,2,18), the
insulinoma cell lines showed a decreased G0/G1 population
and an increased proportion (24–46%) of cells actively
engaged in the cell cycle (S and G2/M) (Fig. 1A).
This enhanced cell cycle progression was conﬁrmed by
analysis of the growth curves of the four cell lines (Fig.
1B). By day 6, the two rat cell lines were expanded 24- to
25-fold compared with an only 4- to 6-fold increase for the
mouse cell lines.
Comprehensive analysis of the G1/S proteome in the
four insulinoma cell lines. As detailed in Fig. 2A, large
T-antigen was expressed in the two mouse lines, BTC3 and
MIN6 cells, consonant with the use of T-antigen to derive
these cells (4,5). As expected, the normal rat and mouse
islets and the two rat insulinoma lines lacked T-antigen.
The pocket proteins, pRb, p107, and p130 that serve as the
ﬁnal common pathway to G1/S control (Fig. 2A, middle left
panel), all were present in the four insulinoma cell lines. In
contrast to an anticipated increase in pRb phosphorylation
in all four lines, phospho-pRb was present in BTC3 cells
and MIN6 cells and absent in INS1 and RINm5F cells.
Moreover, pRb and p107 appeared to be expressed at
higher levels in the insulinoma cell lines than normal
islets. Higher–molecular weight bands present in the p107
and p130 blots may represent phosphorylated forms. As
can be seen in Fig. 2A (bottom left panel), pRb in INS1
cells was readily phosphorylated by overexpression of
cdk-4 and cyclin D1, indicating that there are no intrinsic
abnormalities in pRb that prevent its phosphorylation.
Thus, the pathophysiology underlying the changes in the
pocket proteins remains unexplained for any of the four
insulinoma cell lines.
Figure 2A, right panel, displays for the ﬁrst time the E2F
family in the four cell lines. All six appear to be present in
the cell lines. Several, such as E2F2, -4, and -6, appear to be
expressed at higher levels in the cell lines than in primary
islets. Conversely, E2F1 appeared to be reduced in the
murine cell lines compared with normal islets.
The D-cyclins and their cognate cyclin-dependent ki-
nases (cdks) are shown in Fig. 2B. Cyclin D1, reported to
be increased in human insulinoma (19), was reduced in all
four rodent cell lines. Cyclin D2, essential for the murine
-cell cycle progression (20,21), was undetectable in two of
the four cell lines, BTC3 and RINm5F cells. Interestingly,
despite their common T-antigen origins, the two murine cell
lines displayed opposite cyclin D2 proﬁles: BTC3 lacked
cyclin D2, whereas MIN6 cells expressed easily detectable
cyclin D2. Similarly, despite their common radiation-induced
pathogenesis, the same was observed for INS1 versus
RINm5F cells. Finally, cyclin D3, generally felt to be the least
important of the three D cyclins (21,22), was substantially
increased in the two rat cell lines.
Figure 2B also demonstrates that cdk-4 and cdk-6 are
unequivocally increased in all four insulinoma cell lines.
FIG. 3. The effect of cell cycle phase on the seven key pro-cell cycle molecules in INS1 cells. A: FACS histogram of INS1 cells grown under
randomly cycling nonsynchronized (Non-Sync) conditions, under conditions of growth arrest (Arrested) induced by exposure to 2.8 mmol/l
glucose and serum withdrawal for 96 h, and after release from arrest (Released) by the addition of complete medium (see RESEARCH DESIGN AND
METHODS) for 24 h. B: Representative immunoblots of the seven key G1/S molecules under each of these three conditions, compared with extracts
of rat islets. As can be seen, whereas some changes do occur in the G1/S molecules with growth arrest, they are minor compared with their marked
overexpression compared with rat islets.
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and for their cognate partners, cyclin E and A. Thus, of the
seven potential G1/S cyclins and cdks (cdk1, -2, -4, and -6
and cyclins A, D, and E) all seven are increased in each of
the four cell lines.
The INK4 and KIP/CIP/WAF families are inhibitors of
the cyclin-cdk proteins. Figure 2D demonstrates that many
of these are increased in the four insulinoma cell lines. In
addition, the -cell cycle inhibitor, menin, which transcrip-
tionally activates p18Ink4 and p27kip, is present and is
increased in the two rat cell lines. Similarly, the tumor
suppressor p53 is increased in all four cell lines. Its E3
ligase, MDM2, was increased in the mouse lines but
unaltered in the rat lines (Fig. 2E). Finally, the four Id
proteins, which interact with the pocket proteins to regu-
late their DNA binding and differentiation (23), were
variably present but showed no consistent pattern.
The increase in the seven key G1/S molecules is inde-
pendent of cell cycle phase. The seven “candidate cell
cycle activators” in Fig. 2B and C served as the focus of the
remainder of the study. To determine whether the increase
in the seven key G1/S molecules was an intrinsic feature
on the insulinomas or reﬂected only certain cell cycle
phases in randomly cycling cells, we compared their level
of expression in randomly cycling, starvation-arrested, and
resynchronized INS1 cells to levels observed in isolated rat
islets. As can be seen in Fig. 3, although there were minor
changes among the former three conditions, under all
conditions, levels were markedly higher in INS1 cells than
in rat islets.
Effect of different glucose concentrations on the
expression of the seven candidate cell cycle activa-
tors. Because each of the cell lines was grown using
different glucose concentrations and because glucose is
known to drive rodent -cell replication (24–29), deter-
mining whether any of the cdk or cyclin changes observed
above reﬂected culture conditions rather than intrinsic
insulinoma biology was important. We therefore com-
pared the cell cycle distribution of the INS1 cells and
primary rat islets cultured in 5.5 versus 11 mmol/l glucose
(Fig. 4A). In normal rat islet cells, S phase was approxi-
mately doubled in 11 compared with 5.5 mmol/l glucose,
although this difference did not achieve statistical signiﬁ-
cance. Thus, as anticipated, higher glucose levels favor
-cell replication. The expression of cyclins and cdks were
studied in INS1 cells and rat islet cells in both glucose
concentrations. Cyclins A, E, and D3 were found to be
upregulated in normal islet cells by higher glucose con-
centration, but the expression did not approach the levels
of expression of these proteins observed in INS1 cells (Fig.
4B). Thus, although glucose can stimulate proliferation, it
is not the cause of the striking upregulation of the seven
candidate cell cycle activators. Rather, these are intrinsic
features of the four cell lines.
Overexpression of the seven candidate cell cycle
activators mimics proliferation rates in INS1 cells. To
determine whether any of the seven was capable of
inducing cell cycle progression, they were overexpressed
individually in isolated primary rat islets using adenovirus.
“Ad.cyclin D” in the experiments refers to cyclin D1.
Figure 5A conﬁrms that each of the seven proteins was
overexpressed by the appropriate adenovirus. The effect
of overexpression of each of the seven molecules on islet
cell proliferation was studied by FACS. Modest but statis-
tically signiﬁcant increases in proliferation were observed
when cyclin E or cyclin D was overexpressed individually
but not by the overexpression of the other proteins (Fig.
5B). In contrast, the maximum rate of proliferation
achieved using combinations of cell cycle agonists closely
resembled that seen in INS1 cells (Fig. 5C). Therefore, the
seven cell cycle combination (Ad.Combo) was used for
subsequent experiments. In a dose-response study, the
minimal MOI of the Ad.Combo that was able to induce
maximal proliferation was 250 or lower (Fig. 5D).
FIG. 4. The effect of glucose on key cell cycle proteins in rat islets and INS1 cells. A: Cell cycle distribution of rat islet cells and INS1 cells at 5.5
and 11 mmol/l glucose. B: The effect of glucose on the expression of the seven candidate cell cycle activators plus cyclins D1 and D2. 5.5 and 11
refer to 5.5 and 11 mmol/l glucose concentrations. Each experiment was performed three times.
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DIABETES, VOL. 57, NOVEMBER 2008 3061Insulin and Ki-67 double immunoﬂuorescent staining
conﬁrmed that proliferation was occurring in -cells: An
average of 26  3.6% of -cells were proliferating, a 13-fold
increase compared with Ad.GFP or nontransduced con-
trols (Fig. 6A). In parallel, BrdU staining revealed compa-
rable results: An average of 20  4.1% of -cells were BrdU
positive, a sevenfold increase compared with Ad.GFP
control (Fig. 6B).
Cell cycle–driven -cell proliferation does not induce cell
death. To establish whether overexpression of the seven
candidate activators induced apoptosis, we double-stained
sections of rat islets transduced with Ad.GFP, Ad.Combo, or
FIG. 5. Consequences of cyclin-cdk overexpression in rat islets. A: Documentation of overexpression of the seven candidate cell cycle activators. B: The effect
of individual overexpression of the seven cell cycle activators at 100 MOI (left) or 700 MOI (right) on rat islet cell proliferation as measured by ﬂow
cytometry.*P<0.05.Eachexperimentwasperformedthreetimes. C:Flowcytometricanalysisoftheeffectofcombinedoverexpressionofthesevencellcycle
activators on rat islet cell proliferation. Each condition used a maximum of 700 MOI, with 100 MOI of each virus shown on the x-axis. *P < 0.05 vs. Ad.GFP;
#P < 0.05 compared with INS1 cells. Each experiment was performed three to ﬁve times. D: The effect of three different adenovirus MOI on rat islet cell
proliferation. The numbers of MOI used for these experiments were 250, 500, and 700 MOI. Each bar represents four experiments.
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of cells doubly positive for insulin and TUNEL was low:
1.03  0.9, 1.34  0.7, and 0.85  0.5% in control, Ad.GFP,
and Ad.Combo transduced islets, respectively (Fig. 7).
Accelerated -cell proliferation may be associated
with mild dedifferentiation. To investigate whether cell
cycle activators led to dedifferentiation in rat -cells
(23,30), we examined -cell differentiation markers in
rapidly proliferating Ad.Combo-transduced primary rat
islets and compared them with Ad.GFP-transduced and
nontransduced control islets. As shown in Fig. 8A,o ft h e
ﬁve -cell–speciﬁc mRNAs examined (insulin, Glut2, Pdx1,
Sur1, and Kir6.2) and glucagon, no signiﬁcant differences
were observed between Ad.Combo-transduced islets ver-
FIG. 5. Continued
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itself did reduce Pdx1, Kir6.2, and glucagon in Ad-trans-
duced islets.
GSIS studies (Fig. 8B) demonstrated robust insulin secre-
tion from uninfected and Ad.GFP-transduced islets. Ad-
.combo-transduced islets displayed a trend toward higher
basal insulin secretion and lower GSIS, but these differences
from the two control groups were not signiﬁcant.
Ad.combo-transduced islets function normally in vivo.
The studies reported this far suggested that Ad.combo-
transduced islets might be slightly dedifferentiated (Fig.
8A and B) or, alternatively, because of their accelerated
proliferation, might have an engraftment or functional
advantage in vivo. To explore these possibilities more
deﬁnitively, transplant of Ad-transduced rat islets into
streptozotocin-induced diabetic NOD-SCD mice was per-
formed (Fig. 8C). Sham-transplanted animals displayed
glucoses in the 400–500 mg/dl range for the 4 weeks of the
study. Animals receiving 200 control IE displayed near-
normal postprandial glucose values, whereas those receiv-
ing 100 and 50 control IE displayed progressively poorer
glycemic control. Importantly, animals receiving equiva-
lent numbers (50, 100, or 200) of rat IE transduced with the
Ad.combo performed neither better nor worse than con-
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FIG. 6. The effect of combined overexpression of the seven cell cycle activators on rat -cell proliferation. -Cell proliferation was measured by
double staining for Ki-67 and insulin (A) or BrdU and insulin (B). Representative examples are shown in the top panels and quantitation in the
bottom panel and represented by percentage of double positives Ki-67/insulin or BrdU/insulin. n indicates the number of experiments performed.
(Please see http://dx.doi.org/10.2337/db08-0393 for a high-quality digital representation of this ﬁgure.)
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that although Ad.combo did not enhance functional
engraftment, there was no net increase or decrease in
-cell differentiation. However, without deﬁning -cell
mass in the islet grafts, it is possible that Ad.combo-
induced proliferation in vivo expanded -cell mass
substantially, masking a reduction in -cell differentia-
tion or function.
DISCUSSION
This study represents the ﬁrst comprehensive molecular
characterization of G1/S cell cycle regulation in continu-
ously proliferating -cell lines. We have 1) identiﬁed
striking differences in cell cycle control molecules in
insulinoma cell lines compared with primary -cells; 2)
identiﬁed seven candidate cell cycle activators that may
contribute to cell cycle progression in rodent insulinoma
cell lines; 3) formulated a strategy to dramatically stimu-
late proliferation of primary rat -cells to the level ob-
served in insulinoma cell lines; 4) shown that this does not
enhance cell death or greatly impair differentiation or
function in vitro; and 5) shown that transduction with
seven cell cycle activators neither enhances nor attenuates
rat islet function in vivo. These observations may be
directly applicable to efforts to create continuously grow-
ing human -cell lines and to expand human -cell mass
for -cell replacement treatment of diabetes.
Despite the fact that rodent insulinoma cell lines were
developed 20–30 years ago (3–7), the molecular events
responsible for their ability to replicate continuously for
decades remain entirely unknown. We have observed that
the large majority of rat and mouse islet cells are in G0/G1,
which agrees nicely with data published using other
techniques, conﬁrming the slow rate of normal -cell
proliferation (18). In contrast, for rodent insulinoma cells,
a substantial proportion are not arrested but are instead
actively cycling. The rat lines, INS1 and RINm5F, replicate
far more rapidly than the mouse lines, MIN6 and BTC3.
Whether this difference in proliferation rate is due to the
different species from which they are derived, to the
different transformation processes (radiation versus T-Ag)
through which they were generated, or to other factors
remains unknown. Interestingly, the MIN-6 cells displayed
a particularly large percentage of cells in G2/M (Fig. 1A),
consistent with either a particularly accelerated G1/S
transition or a partial block at G2/M. Growth curves show
that MIN6 cells grow at a rate comparable with BTC3 cells
(Fig. 1B), suggesting that MIN-6 cells have acquired addi-
tional mutations delaying the G2/M transition, in addition
to those involved in G1/S transition described herein.
Importantly, the marked abnormalities in cell cycle con-
trol in these insulinoma cell lines mean that these cell lines
must be used cautiously, if at all, as models of normal
growth regulatory mechanisms.
We next comprehensively surveyed 32 regulatory pro-
teins of the G1/S transition in each of the four insulinoma
lines. This revealed important and unexpected ﬁndings.
First, pRb was unexpectedly hypo- and not hyperphospho-
rylated in both of the rat insulinoma cell lines, those that
have the most rapid proliferation rate. We hypothesized
that this might result from pRb mutations that rendered
pRb nonphosphorylatable. However, we easily were able
to induce pRb phosphorylation in these same INS1 cells by
combined overexpression of cdk-4 and cyclin D1. This
indicates that pRb phosphorylation is not required for cell
cycle progression in these cell lines. Second, despite their
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differences. The most striking of these is the abundance of
cyclin D2 in INS1 cells, but the complete absence of cyclin
D2 in RINm5F cells. Similarly, for the two mouse lines,
MIN6 cells contain abundant cyclin D2, yet BTC3 cells
completely lack cyclin D2. These observations are partic-
ularly noteworthy because cyclin D2 has been described
as being essential for cell cycle progression for normal
mouse -cell replication (20,21). This clearly does not
apply to rodent insulinomas. The existence of multiple
molecular differences among cells that were derived from
the similar or identical parental lines (MIN6 and BTC3;
INS1 and RINm5F) is consonant with human cancers in
which genomic instability with the consequent ongoing
accumulation of multiple mutations is characteristic of
transformed cells (8–10). It is also consistent with differ-
ing insertional mutagenic events in the separately derived
RIP-Tag cell lines and/or different radiation mutagenic
events in the two rat insulinoma cell lines. Third, cell cycle
progression in the four rodent cell lines is accelerated
despite a generalized increase in the upstream cell cycle
inhibitors (the three pocket proteins, the four INK4s, and
the three CIP/KIPs). We hypothesize that this reﬂects an
eager, but futile, attempt to induce cell cycle arrest.
Fourth, and most importantly, this survey reveals a
marked increase in seven very plausible mediators of cell
cycle progression: cdk1, cdk2, cdk4, cdk6, cyclin A, cyclin
E, and cyclin D.
Importantly, despite the normal use of high glucose
media for these cell lines, the upregulation of the seven
proteins is not mediated by glucose levels: exposure to
increased glucose concentrations induced mild upregula-
tion of cyclin A, cyclin D3, and cyclin E in primary rat
islets in agreement with previous reports (24) but not to
the levels observed in insulinoma cell lines. Equally im-
portantly, the changes observed in the rodent insulinoma
cell lines were independent of cell cycle stage, occurring
in randomly cycling cells, starvation-arrested cells, and
synchronized cells. Collectively, these observations indi-
cate that the upregulation of the seven pro-cell cycle
molecules is an intrinsic feature of these cells, indepen-
dent of cell cycle stage or nutritional status.
Proliferation of primary rat -cells could be stimulated
to levels observed in INS1 cells by forced expression of the
seven cell cycle activators in combination. This was con-
ﬁrmed using FACS, Ki-67, and BrdU immunostaining.
Gratifyingly, the induced increase in proliferation had
no effect on -cell death. However, subtle changes in
differentiation markers and GSIS in vitro were suggestive
of -cell dedifferentiation. To explore this issue more
deﬁnitively, we introduced the Ad.combo into normal rat
islets and observed their function in vivo. These studies
can be interpreted in two ways. On one hand, Ad.combo
did not adversely affect the apparent engraftment or net
function of normal rat islets in vivo, suggesting that the
Ad.combo was not intrinsically dedifferentiating in overall
terms. Of course, because -cell mass was not measured in
the grafts, it is possible that -cell mass was higher in the
Ad.combo-transduced grafts and therefore that insulin
secretion per -cell was reduced. On the other hand, the
proliferative advantage of the Ad.combo did not enhance
the apparent overall function of the rat islets.
We interpret these in vitro and in vivo observations in
several ways. First, although a combination of seven cell
cycle molecules may be able to stimulate cell cycle pro-
gression in vitro, it is clear from Fig. 5B and C that the
addition of fewer pro-cell cycle molecules may sufﬁce to
stimulate proliferation effectively. We have recently re-
ported that the addition of only two of these, cdk-6 and
cyclin D1, clearly enhance the engraftment and function of
human islets in the same in vivo model (31). Thus,
evaluation of additional combinations of the seven cell
cycle agonists in vitro and in vivo is warranted. This will be
difﬁcult, because the number of possible combinations is
7! (seven factorial), adjusted for random order, or 120.
Second, adenovirus delivered at 250 MOI may have ad-
versely affected -cell function. Because cell cycle mol-
ecule–induced proliferation was maximized by 250 MOI
(Fig. 5A and D), it is possible that lower MOI may permit
the beneﬁcial effects of cell cycle molecule delivery with-
out the adverse effects. Third, although we have observed
additivity among the seven members studied (Fig. 5B and
C), we have not observed evidence of synergy among
them: additional combinations may reveal such synergy.
And fourth, aggressive replication rates may be unneces-
sary: slower replication rates may be perfectly satisfactory
for expanding -cell mass in vitro and in vivo while
retaining differentiation/function. At a molecular level, the
nature of a link between differentiation and proliferation,
or even the existence of one in many cell types, is
undeﬁned. These observations suggest that there is an
opportunity for further optimizing the MOI and duration of
the transduction conditions and for further exploring the
potential link between differentiation and proliferation in
-cells.
These studies increase available knowledge regarding
cell cycle control in rodent insulinoma lines but also leave
a number of questions unanswered. For example, they are
conﬁned to G1/S control molecules and leave unexplored
other potential critically important pathways, such as
telomere replication and extension, DNA stability, and
signaling pathways upstream of the seven cell cycle mol-
ecules. Furthermore, although each of the seven candi-
dates is reproducibly increased in the insulinoma lines and
although overexpression of these seven in combination
induces dramatic -cell replication, these studies shed no
light on which of these, if any, is actually responsible or
essential for cell cycle progression in rodent insulinoma
cell lines. Equally importantly, although each of the seven
candidates is a normal cell cycle component, each has also
been implicated in oncogenic contexts. An additional
question relates to the use of adenovirus in particular, and
gene therapy in general, as therapies for diabetes. Finally,
and perhaps most importantly, whether the ﬁndings de-
scribed herein in rodent islets will apply to human -cell
replication is unknown. These areas represent fertile
ground for future study.
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